We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

1 hedge funds and large institutions have $10.2K invested in Apellis Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 279 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 323 → 1 (-322)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $5.56B → $10.2K (-$5.56B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 279

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

109.78% less ownership

Funds ownership: 109.78% → 0% (-110%)

Holders
1
Holders Change
-322
Holders Change %
-99.69%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
279
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$545M
2
ACA
Avoro Capital Advisors
New York
-$492M
3
Morgan Stanley
Morgan Stanley
New York
-$404M
4
State Street
State Street
Massachusetts
-$275M
5
UBS Group
UBS Group
Switzerland
-$250M
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
51
Susquehanna International Group
Pennsylvania
– -$13.7M -340,086 Closed
GF
52
Gabelli Funds
New York
– -$12.9M -321,200 Closed
BBL
53
Beck Bode LLC
Massachusetts
– -$12.6M -312,841 Closed
MC
54
Meteora Capital
Florida
– -$12.1M -300,000 Closed
OCAI
55
O'Connor Alternative Investments
New York
– -$12.1M -300,000 Closed
JF
56
Jump Financial
Illinois
– -$11.7M -291,488 Closed
RhumbLine Advisers
57
RhumbLine Advisers
Massachusetts
– -$11.1M -275,540 Closed
GIP
58
Granite Investment Partners
California
– -$9.33M -231,917 Closed
Legal & General Group
59
Legal & General Group
United Kingdom
– -$9.18M -228,255 Closed
WCMNY
60
Westchester Capital Management (New York)
New York
– -$9.15M -227,489 Closed
Nuveen
61
Nuveen
North Carolina
– -$8.86M -220,114 Closed
Bank of Montreal
62
Bank of Montreal
Ontario, Canada
– -$8.65M -215,041 Closed
SFM
63
Sphera Funds Management
Israel
– -$8.65M -214,914 Closed
TI
64
Trexquant Investment
Connecticut
– -$8.26M -205,219 Closed
GCIA
65
Gabelli & Co Investment Advisers
New York
– -$8.07M -200,600 Closed
CCM
66
Chicago Capital Management
Illinois
– -$5.76M -190,000 Closed
D.E. Shaw & Co
67
D.E. Shaw & Co
New York
– -$7.52M -186,853 Closed
Ameriprise
68
Ameriprise
Minnesota
– -$7.39M -183,578 Closed
Rafferty Asset Management
69
Rafferty Asset Management
New York
– -$7.26M -180,471 Closed
FT
70
Fiduciary Trust
Massachusetts
– -$7.25M -180,161 Closed
UBS AM
71
UBS AM
Illinois
– -$7.24M -179,953 Closed
GLAM
72
Gardner Lewis Asset Management
Pennsylvania
– -$6.64M -165,000 Closed
RSCM
73
Rock Springs Capital Management
Maryland
– -$6.55M -162,750 Closed
Mackenzie Financial
74
Mackenzie Financial
Ontario, Canada
– -$6.17M -153,330 Closed
PMAM
75
Picton Mahoney Asset Management
Ontario, Canada
– -$6.03M -150,000 Closed
1 2
3
4 5

APLS Hedge Fund Activity: Q2 2026 in Review

1 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2026, worth a combined $10.2K — down 100% from $5.56B a quarter earlier.

Sellers outnumbered buyers: 279 funds closed out of APLS and 0 opened new positions — a net loss of 279 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $545M sold.

  • 1 institutional investor held Apellis Pharmaceuticals (APLS) as of Q2 2026, down from 323 in Q1 2026.
  • Funds reported $10.2K of Apellis Pharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Apellis Pharmaceuticals positions in Q2 2026 and 279 closed out, a net change of -279 holders.
  • The largest Apellis Pharmaceuticals seller in Q2 2026 was BlackRock, an estimated $545M sold.

Based on aggregated 13F filings for Q2 2026.